CINECA IRIS Institutional Research Information System

SMEDILE, Antonina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.510
EU - Europa 11.462
AS - Asia 6.508
SA - Sud America 321
AF - Africa 277
OC - Oceania 159
Continente sconosciuto - Info sul continente non disponibili 19
Totale 32.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.032
CN - Cina 3.540
IT - Italia 1.974
DE - Germania 1.848
SE - Svezia 1.258
IE - Irlanda 1.136
FR - Francia 975
UA - Ucraina 826
FI - Finlandia 643
KR - Corea 573
GB - Regno Unito 545
SG - Singapore 410
JP - Giappone 400
DK - Danimarca 374
CA - Canada 364
PL - Polonia 361
IN - India 335
VN - Vietnam 321
RU - Federazione Russa 279
AT - Austria 270
TR - Turchia 253
ES - Italia 244
NL - Olanda 184
TW - Taiwan 182
BR - Brasile 175
AU - Australia 145
HK - Hong Kong 120
GR - Grecia 95
EG - Egitto 91
BE - Belgio 86
MX - Messico 83
RO - Romania 77
CH - Svizzera 70
ID - Indonesia 70
IR - Iran 52
AR - Argentina 42
PK - Pakistan 37
CO - Colombia 36
CZ - Repubblica Ceca 35
PT - Portogallo 34
HU - Ungheria 31
PH - Filippine 30
KE - Kenya 28
TH - Thailandia 28
UZ - Uzbekistan 27
NO - Norvegia 25
MY - Malesia 24
HR - Croazia 23
IQ - Iraq 22
CL - Cile 21
CM - Camerun 19
EC - Ecuador 18
EU - Europa 18
IL - Israele 16
PE - Perù 15
ZA - Sudafrica 15
NZ - Nuova Zelanda 14
MN - Mongolia 13
NG - Nigeria 13
MA - Marocco 12
RS - Serbia 12
MU - Mauritius 11
VE - Venezuela 11
ET - Etiopia 10
SD - Sudan 10
SI - Slovenia 10
BG - Bulgaria 9
TN - Tunisia 9
ZM - Zambia 9
BF - Burkina Faso 8
DZ - Algeria 8
CU - Cuba 7
SA - Arabia Saudita 7
BY - Bielorussia 6
CR - Costa Rica 6
GT - Guatemala 6
MK - Macedonia 6
SN - Senegal 6
BA - Bosnia-Erzegovina 5
BD - Bangladesh 5
LV - Lettonia 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
TL - Timor Orientale 5
YE - Yemen 5
AE - Emirati Arabi Uniti 4
GH - Ghana 4
GM - Gambi 4
PR - Porto Rico 4
CI - Costa d'Avorio 3
CY - Cipro 3
KZ - Kazakistan 3
LB - Libano 3
LU - Lussemburgo 3
MZ - Mozambico 3
OM - Oman 3
CD - Congo 2
GA - Gabon 2
GE - Georgia 2
JO - Giordania 2
Totale 32.218
Salva come PNG Salva come JPEG
Città #
Beijing 1.800
Chandler 1.472
Ann Arbor 1.459
Dublin 1.122
Fairfield 669
Houston 624
Villeurbanne 551
Jacksonville 517
Dearborn 488
Ashburn 472
Torino 458
Wilmington 448
Redwood City 435
Woodbridge 394
Medford 379
Princeton 376
Nyköping 325
Seattle 273
Warsaw 264
Vienna 251
Shanghai 239
Singapore 236
Pisa 234
Cambridge 198
Guangzhou 187
Fremont 172
Dong Ket 162
Ottawa 162
Boston 141
Milan 120
Nanjing 109
Rome 105
Boardman 103
New York 103
Taipei 101
Tokyo 86
Toronto 75
Verona 71
Wuhan 71
Hangzhou 65
Chengdu 64
Stockholm 57
Istanbul 53
Norwalk 53
West Jordan 53
Hefei 52
Zhengzhou 52
Munich 51
San Diego 51
Hanoi 50
Barcelona 49
Pune 49
Turin 47
Brussels 46
Kunming 44
London 44
Jakarta 42
Chongqing 40
Seoul 40
Ankara 39
Helsinki 39
Madrid 39
Nürnberg 38
Bucharest 37
Los Angeles 37
Jinan 36
Washington 35
Paris 34
Phoenix 34
Central District 32
Delhi 31
Falls Church 31
Duncan 30
Fuzhou 30
Amsterdam 28
Cairo 28
Hyderabad 28
Lachine 28
San Mateo 28
Bengaluru 27
Düsseldorf 27
Naples 27
Berlin 26
Changsha 26
Mountain View 26
Silver Spring 26
Bologna 25
Moscow 24
Changchun 23
Melbourne 23
Sydney 23
Tianjin 23
Hanover 22
Nanchang 22
Rotterdam 22
Chicago 21
Nanning 21
Rochester 21
Hebei 20
Ho Chi Minh City 20
Totale 17.611
Salva come PNG Salva come JPEG
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.715
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 976
Hepatitis delta virus diagnosis. 707
Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response 619
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma 560
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 558
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis 533
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 497
Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. 410
Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin for hepatocellular carcinoma detection 351
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 351
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 346
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 329
Chronic hepatitis B therapy: available drugs and treatment guidelines. 326
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. 316
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING. 314
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 304
Endocrine manifestations of chronic HCV infection 284
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 277
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. 261
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 258
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 250
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 223
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 213
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 211
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 192
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B 190
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 184
AISF position paper on liver disease and pregnancy. 184
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 183
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 181
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 178
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 172
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 168
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 165
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 158
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 158
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 153
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
F-8 Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin 150
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 147
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 147
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 145
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 141
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 141
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 139
Pegylated interferon therapy of chronic hepatitis D: In need of revision 139
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 137
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 135
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. 134
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 129
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 127
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 127
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 127
Antibodies against GOR in patients undergoing orthotopic liver trasplantation (OLT) 126
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 126
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Italian blood donors with anti-HBc and occult hepatitis B virus infection 124
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. 124
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 123
Inhibition of chymase-dependent production of kidney angiotensin II improves renal sodium handling and prevents ascites in experimental liver cirrhosis 122
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 122
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 121
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA 121
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 115
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 114
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 113
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 113
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 113
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence 112
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 112
CLINIC EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HBV CHRONIC INFECTION 111
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. 111
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 108
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 107
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 106
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 106
THE ROLE OF ANTI-IFI16 ANTIBODIES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD) 105
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 104
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 103
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 103
Etiological factors of chronic hepatitis in Italy: a 2014 national survey 103
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 103
CLINICAL EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HBV INFECTION 101
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 101
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 100
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 99
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 99
Liver transplant for viral hepatitis. Recurrence of reinfection 98
Inactive hepatitis B virus carriers: a favourable clinical condition 97
la reinfezione virale nel post -trapianto 97
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 97
Totale 21.211
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.836
article - articoli 0
book - libri 0
conference - conferenze 26.687
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.809 0 184 262 548 400 809 521 362 499 534 347 343
2020/20213.899 407 317 294 242 359 257 312 179 377 331 307 517
2021/20225.120 232 273 280 451 362 303 408 397 317 483 809 805
2022/20235.454 592 408 190 467 446 1.238 511 348 527 209 313 205
2023/20242.992 342 427 188 204 174 363 163 225 32 215 246 413
2024/2025226 179 47 0 0 0 0 0 0 0 0 0 0
Totale 33.550